肥厚型心肌病患者静息脉压和运动诱导的血压异常之间的关系

目的:探讨肥厚型心肌病患者静息脉压和运动诱导的血压异常之间的关系。方法:根据Bruce方案,对70例2007年1月至2012年1月在我院治疗的肥厚型心肌病患者进行症状限制运动试验,监测患者的血液动力学指标,即分别在患者仰卧休息和运动结束后测量血压。结果:肥厚型心肌病患者中,运动后血压反应异常者与正常者相比,前者的静息脉压显著高于后者。表现出运动性非正常血压反应的肥厚型心肌病患者,静息脉压明显高于无运动性非正常血压反应患者(P=0.007)。根据二分类Logistic回归分析,控制年龄、性别、左室后壁厚度、室间隔厚度、左室流出道梗阻等混杂因素后,静息脉压可以有效预测肥厚型心肌病患者的运动性非正常血压反应(P=0.016)。结论:与传统的收缩压、舒张压以及平均动脉压相比,静息脉压可作为一个有效的辅助检测指标预防肥厚型心肌病患者心脏猝死的发生。     

心尖肥厚型心肌病的临床特征及治疗

目的:总结心尖肥厚型心肌病的临床特征及治疗方法.方法:回顾性分析我院2008年6月至2012年2月期间经心脏超声或左室造影证实的33例心尖肥厚型心肌病患者的临床特征及治疗情况.结果:患者的临床症状表现为以胸闷、气短为主者20例;心前区不适4例;心前区疼痛5例;乏力2例;心悸l例;发现心电图异常前来就诊l例.32例患者行左室造影诊断为心尖肥厚型心肌病.l例因肾功能不全,未行左室造影,但经心脏超声诊断为心尖肥厚型心肌病.27例患者服用β-受体阻滞剂,2例患者服用钙离子拮抗剂,4例患者因心率慢,未服用药物,临床随访1～36(平均16.7± 4.1)个月,临床症状均明显缓解.结论:β-受体阻滞剂和钙离子拮抗剂均适用于治疗心尖肥厚型心肌病.     

肥厚型心肌病患者运动血压反应异常的两类表现及其相关因素分析

目的:运动血压反应不足及运动后恢复期血压降低是肥厚型心肌病(HCM)患者常见的异常表现,本研究的目的是分析HCM患者这两类异常血压反应表现的相关因素及其与心肺运动功能的关系.方法:回顾性研究2018年4月至2020年1月期间在阜外医院功能检测中心行心肺运动试验(CPET)的HCM患者219例.111例行CPET的性别、...     

肱动脉内皮依赖性舒张功能鉴别左室舒张功能假性正常化的价值

目的:研究冠心病患者左室舒张功能假性正常化与肱动脉内皮依赖性舒张功能的关系。方法:将75例行选择性冠状动脉造影的患者按冠状动脉病变程度分为单/双支病变组和三支病变组两组,选取48例健康志愿者作为对照组。检测左室舒张功能指标二尖瓣口血流频谱E峰、A峰、E/A比值,同时观察休息时肱动脉反应性充血后内径变化率。结果:单/双支病变组(第一组)E峰、E/A比值下降,肱动脉反应性充血后内径变化率低于正常对照组(P<0.05);三支病变组(第二组)E峰、E/A值无明显改变,肱动脉反应性充血后内径变化率明显低于对照组(P<0.01)。结论:肱动脉内皮依赖性舒张功能可作为鉴别冠心病左室舒张功能假性正常的指标。     

超声心动图测量二尖瓣环位移评价左室舒张功能

本文用超声心动图测量正常人和高血压病患者二尖瓣环位移,探讨该方法评价左室舒张功能价值。结果表明：高血压病组舒张期二尖瓣环位移最大幅度低于正常组,左房收缩引起二尖瓣环位移及Ａｔ／Ｔ比值均高于正常组,两组Ａｔ／Ｔ与Ａ／Ｅ之间均存在良好线性关系,Ａｔ／Ｔ诊断左室舒张功能异常的敏感性和特异性分别是９３％和８６％。     

压力超负荷心衰小鼠模型的心脏结构和功能病理进程特征

目的建立小鼠心衰模型,应用超声影像学和病理学技术综合评价疾病发展过程中的特征性的心脏功能和结构的改变。方法应用主动脉弓缩窄(transverse aortic constriction,TAC)手术技术建立压力超负荷致小鼠心衰模型,造模前0周和造模后2、4、8周采集主动脉弓缩窄处血流多普勒估测血管承受压力,采集B型和M型超声图像评价心脏结构左室收缩功能,采集二尖瓣口血流多普勒结合二尖瓣环组织多普勒评价心脏舒张功能,采集心脏组织进行组织病理学观察。结果超声影像学结果显示术后2、4、8周主动脉血流压力均显著性增加。术后2周主要表现为特征性左室壁代偿性厚度增加、内径减少,收缩功能代偿性增加,但伴随舒张功能受损和心肌纤维化;术后4周为过渡期,主要表现为从室壁肥厚到心室扩张的过渡、收缩功能开始下降、舒张功能持续性受损、心肌进一步纤维化;术后8周为表现为特征性的心室腔扩大,收缩、舒张功能均显著性降低,心肌细胞部分溶解并且显著性纤维化。结论通过评价小鼠主动脉弓缩窄后代偿性心肌肥厚期、过渡期到失代偿扩张型心衰等三个阶段的左室结构和功能,为主动脉弓缩窄模型的在基础和转化研究上的应用提供理论依据。     

超声检测左心室舒张功能的临床意义——85例超声检测结果与冠状动脉造影的对照分析

目的超声心动图检测左心室舒张功能与冠状动脉造影对照分析,探讨超声诊断的临床意义。方法85例临床疑诊冠心病超声检查左心室二尖瓣口舒张早、晚期血流充盈速度E、A两峰峰值,计算E/A比值,其结果分为舒张功能正常和降低两组。全部病人均与冠状动脉造影结果对照分析。结果超声检测左心室舒张功能与冠脉造影均正常24例,均异常53例,共77例,符合率90.59%,不符合8例,占9.41%;本文依据冠脉造影提出超声检测左心室舒张功能正常值;并发现冠心病早期舒张功能降低,且随年龄与病程长短不同。结论超声检测左心室舒张功能的改变与冠脉造影符合率高,舒张功能于冠心病早期可降低,随病程长短不同,为临床对冠心病诊治和预防提供有价值的信息。     

49例先天性胎儿心脏疾病的静脉导管血流频谱分析

目的：不同的胎儿先天性心脏疾病通过不同的作用机制影响到胎儿心脏功能,会引起胎儿体内血循环的不同改变。静脉导管是胎儿血循环中重要的组成,也会随之出现相应的频谱改变。通过对49例合并先天性心脏疾病胎儿的静脉导管血流频谱及参数进行分析,研究胎儿不同类型心脏疾病对静脉导管（DV）血流频谱的影响。方法：选取2009年1月至2012年12月间我们在产前超声检查中发现的49例合并先天性心脏疾病的胎儿,分别测量DV血流频谱并进行参数分析,根据DV频谱是否正常分为两组。结果：DV频谱正常组有29例（59.18%）,表现为S波、a波的流速和方向正常,PVIV及DVRI指标位于正常范围。DV频谱异常组有20例,表现为S波流速降低、a波缺失或反向,PVIV及DVRI升高。结论：DV血流频谱和参数是评价胎儿心功能的良好指标。不同种类胎儿心脏发育异常对胎儿心功能影响的作用机制不同,其DV频谱也有着不同改变。通过对DV频谱的波形和参数分析,了解胎儿心脏异常的病生理机制,评价其严重程度和预后,这对于指导临床诊疗有着重要意义。     

肥厚型心肌病的临床特征及治疗分析

目的:探讨肥厚型心肌病(hypertrophic cardiomyopathy,HCM)的临床特征及治疗方法.方法:回顾性分析我院2008年6月至2012年3月收治的85例经心脏超声或左室造影证实为肥厚型心肌病患者的临床特征及治疗方法和预后.结果:85例肥厚型心肌病患者的临床症状主要表现为胸闷、气短50例(58.8％);心前区疼痛21例(24.7％);心前区不适7例(8.2％);乏力2例(2.4％);心悸2例(2.4％);剑突下疼痛1例(1.2％);发现心电图异常前来就诊2例(2.4％).其中心尖肥厚型心肌病(apical hypertrophic cardiomyopathy)30例(35.3％);合并冠心病4例(血管狭窄小于70％)(4.8％)、心肌桥(myocardial bridge,MB)11例(12.9％)、冠状动脉粥样硬化症4例(4.8％)、冠状动脉粥样硬化症合并MB4例(4.8％)、冠心病合并MB3例(3.5％).67例患者服用β-受体阻滞剂(78.8％),4例患者同时服用β-受体阻滞剂及钙离子拮抗剂(4.8％),4例患者服用钙离子拮抗剂(4.8％),1例患者服用可达龙(1.2％),1例患者同时服用β-受体阻滞剂及可达龙(1.2％),8例患者因心率慢,未服用药物(9.6％).临床随访1～30(平均15.2±4.5)个月,临床症状均明显缓解.结论:HCM症状不典型,β-受体阻滞剂和钙离子拮抗剂在治疗肥厚型心肌病方面疗效肯定.     

49 例先天性胎儿心脏疾病的静脉导管血流频谱分析

目的：不同的胎儿先天性心脏疾病通过不同的作用机制影响到胎儿心脏功能,会引起胎儿体内血循环的不同改变。静脉导 管是胎儿血循环中重要的组成,也会随之出现相应的频谱改变。通过对49 例合并先天性心脏疾病胎儿的静脉导管血流频谱及参 数进行分析,研究胎儿不同类型心脏疾病对静脉导管（DV）血流频谱的影响。方法：选取2009 年1 月至2012 年12 月间我们在产 前超声检查中发现的49 例合并先天性心脏疾病的胎儿,分别测量DV血流频谱并进行参数分析,根据DV频谱是否正常分为两 组。结果：DV频谱正常组有29 例(59.18%),表现为S 波、a 波的流速和方向正常,PVIV 及DVRI指标位于正常范围。DV频谱异 常组有20 例,表现为S波流速降低、a 波缺失或反向,PVIV 及DVRI升高。结论：DV血流频谱和参数是评价胎儿心功能的良好 指标。不同种类胎儿心脏发育异常对胎儿心功能影响的作用机制不同,其DV频谱也有着不同改变。通过对DV频谱的波形和参 数分析,了解胎儿心脏异常的病生理机制,评价其严重程度和预后,这对于指导临床诊疗有着重要意义。     

Cardiomyopathies: a revolution in molecular medicine and cardiac imaging

The cardiomyopathies are defined as: ‘a myocardial disorder in which the heart is structurally and functionally abnormal, in the absence of coronary artery disease, hypertension and congenital heart disease sufficient to cause the myocardial abnormality.’1 With the advent of molecular cardiology and cardiovascular imaging (including MRI and echocardiography) in the last decade, much insight has been gained into the different clinical presentations, its familial and genetic causes and pathophysiology in explaining left ventricular function and prognosis. This has been especially true for hypertrophic cardiomyopathy, but also for dilated cardiomyopathy (DCM) and RV cardiomyopathy.     

Animal models of primary myocardial diseases

Feline and canine cardiomyopathies (primary myocardial diseases) were reviewed and divided into three groups based on the clinical, hemodynamic, angiocardiographic, and pathologic findings: (1) feline and canine hypertrophic cardiomyopathy, (2) feline and canine congestive (dilated) cardiomyopathy, and (3) feline restrictive cardiomyopathy. All three groups consisted predominantly of mature adult male cats and dogs. Cardiomyopathy in the hamster and turkey was also reviewed. The most common presenting signs were dyspnea and/or thromboembolism in the cat, systolic murmurs with gallop rhythms on auscultation, cardiomegaly with (groups 1 and 3) or without (group 2) pulmonary edema, abnormal electrocardiograms, elevated left ventricular end-diastolic pressures, and angiocardiographic evidence of mitral regurgitation with left ventricular concentric hypertrophy (group 1), left ventricular dilatation (group 2), or midventricular stenosis (group 3). Some cats in groups 1 and 3 also had evidence of left ventricular outflow obstruction. The principal pathologic findings in all of the cats and dogs were left atrial dilation, hypertrophy, increased septal:left ventricular free wall thickness ratio with disorganization of cardiac muscle cells (group 1); dilatation of the four chambers with degeneration of cardiac muscle cells (group 2); and extensive endocardial fibrosis and adhesion of the left ventricle (group 3). Aortic thromboembolism was commonly observed in the cats of all three groups. These clinical and pathologic findings indicate that cardiomyopathy in the cat or dog is similar to the three forms of cardiomyopathy in humans (hypertrophic, congestive, and restrictive).     

Cardiac expression of urocortin (Ucn) in diseased heart; preliminary results on possible involvement of Ucn in pathophysiology of cardiac diseases

Recently, several studies reported that urocortin (Ucn) had beneficial effects on cardiovascular system and was expressed both in the normal heart and in the heart of dilated cardiomyopathy (DCM), yet the relationship between high expression of Ucn and pathophysiology of Ucn in diseased heart has been discussed. Thus, the present study was designed to elucidate the expression of Ucn in the diseased heart by immunohistochemical approach using endomyocardial biopsy specimens. The involvement of immunoreactive Ucn in pathophysiology of cardiac disease was evaluated using endomyocardial biopsy specimens obtained from the patients with some heart diseases, including DCM and hypertrophic cardiomyopathy (HCM). Ucn was detected in all endomyocardial biopsy specimens of ventricular tissue obtained from the patients with such cardiac diseases, a specimens of atrial tissue, and normal heart specimens obtained from autopsy cases. In DCM patients, left ventricular end-diastolic pressure significantly elevated in severely stained group. On the contrary, in HCM patients, left ventricular ejection fraction was higher in the severely stained group. Ucn was expressed more abundantly in the diseased heart, especially in HCM and DCM, than in the normal heart. In conclusion, such close relationship between Ucn expression in the heart and cardiac function indicated that clinical features of Ucn resembled those of norepinephrine and Ucn could play a certain pathophysiological roles in the cardiac diseases.     

Diabetic cardiomyopathy? An echocardiographic study of young diabetics.

An echocardiographic study was carried out on 23 young diabetics, 19 of whom had retinopathy. Their diastolic function was analysed by comparing the timing and pattern of mitral valve opening with the pattern of left ventricular wall movement. Only six patients had all their values within the normal range. Fourteen patients had abnormalities similar to those seen in patients with cardiomyopathy; the close time relation between mitral valve movement and wall movement was lost and mitral valve opening delayed in eight patients. Three other patients had considerable outward wall movement before mitral valve opening, which is characteristic of ischaemic heart disease. Although these studies provide no definite evidence of a cause, the abnormalities found may reflect a subclinical diabetic cardiomyopathy due to small-vessel disease.     

Hypertrophic cardiomyopathy associated with left ventricular aneurysm and normal coronary arteries: Case study indicating genetic tendencies of cardiomyopathy

A 50-year-old man presented with hypertrophic obstructive cardiomyopathy (HOC) associated with a left ventricular aneurysm and normal coronary arteries. His history revealed no evidence of myocardial infarction or atypical angina. Physical examination disclosed HOC but did not suggest the presence of an aneurysm. Although the patient was treated medically, heart failure ensued, and he died suddenly while working his farm. Subsequent investigation of the patient's family revealed that three of his five children were also affected by cardiomyopathy, which was especially pronounced in the eldest, a 22-year-old man. The possible hemodynamic relationship between HOC and left ventricular aneurysm is discussed, along with probable indications. The role of left ventricular aneurysm is also presented in relation to the natural history of the disease.     

A novel mouse model of X-linked cardiac hypertrophy

We recovered a novel mouse mutant exhibiting neonatal lethality associated with severe fetal cardiac hypertrophy and with some adult mice dying suddenly with left ventricular hypertrophic cardiomyopathy. Using Doppler echocardiography, we screened surviving adult mice in this mutant line for cardiac hypertrophy. Cardiac dimensions were obtained either from two-dimensional images collected using a novel ECG-gated ultra-high-frequency ultrasound system or by traditional M-mode imaging on a clinical ultrasound system. These analyses identified, among the littermates, two populations of mice: those with apparent cardiac hypertrophy with hypercontractile function characterized by ejection fraction of 75-80%, and normal littermates with ejection fraction of 53-55%. Analysis of the ECG-gated two-dimensional cines indicated that the hypertrophy was of the nonobstructive type. Further analysis of heart-to-body weight ratio confirmed the ultrasound diagnosis of left ventricular hypertrophic cardiomyopathy. Histopathology showed increased ventricular wall thickness, enlarged myocyte size, and mild myofiber disarray. Ultrastructural analysis by electron microscopy revealed mitochondria hyperproliferation and dilated sarcoplasmic reticulum. Genome scanning using microsatellite DNA markers mapped the mutation to the X chromosome. DNA sequencing showed no mutations in the coding regions of several candidate genes on the X chromosome, including several known to be associated with left ventricular hypertrophic cardiomyopathy. These findings suggest that this mouse line may harbor a mutation in a novel gene causing X-linked cardiomyopathy.     

MYBPC3 polymorphism is a modifier for expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy

Clinical phenotype of hypertrophic cardiomyopathy exhibits significant inter- and intra-familial heterogeneities. To test if MYBPC3 polymorphism could modify the expression of cardiac hypertrophy, 226 patients with hypertrophic cardiomyopathy and 226 age- and sex-matched controls were recruited according to the diagnostic criteria of WHO. Genotyping was completed by using PCR, restrictive enzyme digestion, and sequencing. Three polymorphisms of MYBPC3 were studied, only the GG genotype at 18443 in exon 30 associated with thicker left ventricular wall (25.2+/-5.9 mm) in patient group, not the AA and AG genotypes (19.0+/-5.0mm, P<0.001). After multiple regression analysis for adjustment of age and sex, the association remained. No difference was found in the genotype distribution between control and patients. Our results point out that GG genotype of MYBPC3 might be a genetic risk factor for the expression of cardiac hypertrophic phenotype in the patients with hypertrophic cardiomyopathy.     

Gender and aging in a transgenic mouse model of hypertrophic cardiomyopathy

Mutations in the cardiac myosin heavy chain (MHC) can cause familial hypertrophic cardiomyopathy (FHC). A transgenic mouse model has been developed in which a missense (R403Q) allele and an actin-binding deletion in the alpha-MHC are expressed in the heart. We used an isovolumic left heart preparation to study the contractile characteristics of hearts from transgenic (TG) mice and their wild-type (WT) littermates. Both male and female TG mice developed left ventricular (LV) hypertrophy at 4 mo of age. LV hypertrophy was accompanied by LV diastolic dysfunction, but LV systolic function was normal and supranormal in the young TG females and males, respectively. At 10 mo of age, the females continued to present with LV concentric hypertrophy, whereas the males began to display LV dilation. In female TG mice at 10 mo of age, impaired LV diastolic function persisted without evidence of systolic dysfunction. In contrast, in 10-mo-old male TG mice, LV diastolic function worsened and systolic performance was impaired. Diminished coronary flow was observed in both 10-mo-old TG groups. These types of changes may contribute to the functional decompensation typically seen in hypertrophic cardiomyopathy. Collectively, these results further underscore the potential utility of this transgenic mouse model in elucidating pathogenesis of FHC.     

Beneficial effect of ACE inhibitor in congestive heart failure

The effects of captopril, an angiotensin-converting enzyme inhibitor, on congestive heart failure (CHF) were investigated in animal and clinical studies. Congestive heart failure was induced in rats by a combination of pressure and volume overload. Cardiac pressure overload was induced by constricting one renal artery (Goldblatt rat) and volume overload was induced by aorto-caval fistula. Captopril (100 mg/kg/day) was then administered for 14 weeks. Isometric contraction was assessed using isolated left ventricular papillary muscles. The maximum developed tension and the maximum rate of increase in tension (dT/dtmax) were decreased in untreated rats with CHF and improved in captopriltreated rats. The left ventricular myosin isoenzyme pattern was shifted towards V3 in untreated rats with CHF, and was shifted back towards V1 in the captopril-treated rats. In the clinical study, captopril (37.5–75 mg/day) was administered to patients with cardiomyopathy for 12 months. There was no effect on left ventricular mass in hypertrophic cardiomyopathy, although systolic anterior motion of the mitral valve disappeared in one patient. In dilated cardiomyopathy, however, left ventricular mass tended to decrease. These results indicate that captopril has a beneficial effect in congestive heart failure.